Carasent ASA Logo

Carasent ASA

CARA.OL

(2.0)
Stock Price

19,50 NOK

-1.51% ROA

-1.07% ROE

-125.35x PER

Market Cap.

1.301.846.400,00 NOK

1.23% DER

10.22% Yield

-4.09% NPM

Carasent ASA Stock Analysis

Carasent ASA Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Carasent ASA Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.81x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (5%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Revenue Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

4 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

5 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (1.997) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

6 ROE

The stock's ROE indicates a negative return (-5.39%) on shareholders' equity, suggesting poor financial performance.

7 ROA

The stock's ROA (-8.62%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

8 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

9 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

10 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

11 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

Carasent ASA Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Carasent ASA Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Carasent ASA Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Carasent ASA Revenue
Year Revenue Growth
2002 12.545.000
2003 22.111.000 43.26%
2004 37.626.000 41.23%
2005 55.074.000 31.68%
2006 133.328.000 58.69%
2007 210.380.000 36.63%
2008 234.035.000 10.11%
2009 250.429.000 6.55%
2010 227.160.696 -10.24%
2011 242.774.971 6.43%
2012 239.405.900 -1.41%
2013 254.181.307 5.81%
2014 292.382.124 13.07%
2015 302.531.783 3.35%
2016 193.758.719 -56.14%
2017 0 0%
2018 23.965.000 100%
2019 47.927.000 50%
2020 70.576.000 32.09%
2021 137.125.000 48.53%
2022 195.259.000 29.77%
2023 222.080.000 12.08%
2023 243.984.000 8.98%
2024 265.132.000 7.98%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Carasent ASA Research and Development Expenses
Year Research and Development Expenses Growth
2002 0
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 4.533.000 100%
2021 9.810.000 53.79%
2022 10.423.000 5.88%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Carasent ASA General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 0
2003 0 0%
2004 9.507.000 100%
2005 13.004.000 26.89%
2006 16.067.000 19.06%
2007 25.308.000 36.51%
2008 0 0%
2009 77.447.000 100%
2010 65.955.379 -17.42%
2011 0 0%
2012 9.653.283 100%
2013 9.894.795 2.44%
2014 15.338.054 35.49%
2015 15.787.630 2.85%
2016 0 0%
2017 3.884.053 100%
2018 7.583.000 48.78%
2019 4.693.000 -61.58%
2020 14.605.000 67.87%
2021 32.191.000 54.63%
2022 62.259.000 48.3%
2023 21.768.000 -186.01%
2023 55.861.000 61.03%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Carasent ASA EBITDA
Year EBITDA Growth
2002 -76.987.000
2003 -24.892.000 -209.28%
2004 -39.678.000 37.26%
2005 -34.627.000 -14.59%
2006 -20.865.000 -65.96%
2007 -18.078.000 -15.42%
2008 -16.898.000 -6.98%
2009 10.863.000 255.56%
2010 13.439.165 19.17%
2011 33.096.996 59.39%
2012 34.732.838 4.71%
2013 39.256.857 11.52%
2014 19.962.518 -96.65%
2015 130.959.975 84.76%
2016 10.546.338 -1141.76%
2017 20.307.113 48.07%
2018 -3.031.000 769.98%
2019 11.838.000 125.6%
2020 16.044.000 26.22%
2021 27.716.000 42.11%
2022 69.229.000 59.96%
2023 15.200.000 -355.45%
2023 18.853.000 19.38%
2024 33.444.000 43.63%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Carasent ASA Gross Profit
Year Gross Profit Growth
2002 4.776.000
2003 14.752.000 67.62%
2004 26.861.000 45.08%
2005 40.237.000 33.24%
2006 98.126.000 58.99%
2007 156.559.000 37.32%
2008 170.830.000 8.35%
2009 188.444.000 9.35%
2010 167.190.038 -12.71%
2011 172.975.824 3.34%
2012 173.591.610 0.35%
2013 182.551.987 4.91%
2014 193.127.144 5.48%
2015 211.999.042 8.9%
2016 122.640.089 -72.86%
2017 -911.479 13555.06%
2018 18.933.000 104.81%
2019 39.182.000 51.68%
2020 56.787.000 31%
2021 112.899.000 49.7%
2022 161.419.000 30.06%
2023 178.264.000 9.45%
2023 14.753.000 -1108.32%
2024 31.236.000 52.77%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Carasent ASA Net Profit
Year Net Profit Growth
2002 -104.035.000
2003 -43.114.000 -141.3%
2004 -47.558.000 9.34%
2005 -42.456.000 -12.02%
2006 -37.226.000 -14.05%
2007 -138.521.000 73.13%
2008 -57.573.000 -140.6%
2009 -20.429.000 -181.82%
2010 -18.283.379 -11.74%
2011 4.196.066 535.73%
2012 7.062.697 40.59%
2013 4.749.745 -48.7%
2014 -78.734.850 106.03%
2015 60.232.094 230.72%
2016 107.987.593 44.22%
2017 20.307.113 -431.77%
2018 -7.036.000 388.62%
2019 3.212.000 319.05%
2020 -38.131.000 108.42%
2021 -148.000 -25664.19%
2022 31.170.000 100.47%
2023 -17.912.000 274.02%
2023 -46.445.000 61.43%
2024 -22.916.000 -102.67%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Carasent ASA Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 -55
2003 -19 -205.56%
2004 -19 5.26%
2005 -16 -26.67%
2006 -11 -36.36%
2007 -32 64.52%
2008 -10 -244.44%
2009 -2 -350%
2010 -1 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 -4 100%
2015 3 250%
2016 7 66.67%
2017 1 -500%
2018 0 0%
2019 0 0%
2020 -1 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 -1 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Carasent ASA Free Cashflow
Year Free Cashflow Growth
2002 -88.477.000
2003 -36.303.000 -143.72%
2004 -36.109.000 -0.54%
2005 -34.706.000 -4.04%
2006 -20.927.000 -65.84%
2007 -47.671.000 56.1%
2008 -19.780.000 -141.01%
2009 5.164.000 483.04%
2010 5.532.044 6.65%
2011 19.082.253 71.01%
2012 29.428.836 35.16%
2013 26.035.415 -13.03%
2014 22.341.663 -16.53%
2015 -35.100.227 163.65%
2016 -37.171.522 5.57%
2017 -6.404.993 -480.35%
2018 -2.606.000 -145.78%
2019 1.310.000 298.93%
2020 2.630.000 50.19%
2021 -5.747.000 145.76%
2022 -57.950.000 90.08%
2023 -61.954.000 6.46%
2023 -21.047.000 -194.36%
2024 5.494.000 483.09%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Carasent ASA Operating Cashflow
Year Operating Cashflow Growth
2002 -78.241.000
2003 -30.985.000 -152.51%
2004 -28.801.000 -7.58%
2005 -27.381.000 -5.19%
2006 -9.430.000 -190.36%
2007 -23.211.000 59.37%
2008 -11.714.000 -98.15%
2009 10.643.000 210.06%
2010 7.195.773 -47.91%
2011 22.162.154 67.53%
2012 32.287.414 31.36%
2013 29.076.225 -11.04%
2014 24.081.414 -20.74%
2015 -31.557.680 176.31%
2016 -35.589.571 11.33%
2017 -6.404.993 -455.65%
2018 89.000 7296.62%
2019 12.045.000 99.26%
2020 18.761.000 35.8%
2021 32.480.000 42.24%
2022 33.612.000 3.37%
2023 7.249.000 -363.68%
2023 -10.212.000 170.99%
2024 17.494.000 158.37%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Carasent ASA Capital Expenditure
Year Capital Expenditure Growth
2002 10.236.000
2003 5.318.000 -92.48%
2004 7.308.000 27.23%
2005 7.325.000 0.23%
2006 11.497.000 36.29%
2007 24.460.000 53%
2008 8.066.000 -203.25%
2009 5.479.000 -47.22%
2010 1.663.729 -229.32%
2011 3.079.901 45.98%
2012 2.858.578 -7.74%
2013 3.040.810 5.99%
2014 1.739.750 -74.78%
2015 3.542.547 50.89%
2016 1.581.951 -123.94%
2017 0 0%
2018 2.695.000 100%
2019 10.735.000 74.9%
2020 16.131.000 33.45%
2021 38.227.000 57.8%
2022 91.562.000 58.25%
2023 69.203.000 -32.31%
2023 10.835.000 -538.7%
2024 12.000.000 9.71%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Carasent ASA Equity
Year Equity Growth
2002 53.546.000
2003 42.141.000 -27.06%
2004 51.613.000 18.35%
2005 70.282.000 26.56%
2006 184.375.000 61.88%
2007 120.214.000 -53.37%
2008 144.890.000 17.03%
2009 121.431.000 -19.32%
2010 106.590.335 -13.92%
2011 114.033.924 6.53%
2012 114.845.601 0.71%
2013 130.791.319 12.19%
2014 81.902.087 -59.69%
2015 71.466.277 -14.6%
2016 49.049.119 -45.7%
2017 61.266.225 19.94%
2018 91.432.000 32.99%
2019 90.577.000 -0.94%
2020 400.976.000 77.41%
2021 1.171.275.000 65.77%
2022 1.226.602.000 4.51%
2023 1.064.959.000 -15.18%
2023 955.406.000 -11.47%
2024 935.017.000 -2.18%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Carasent ASA Assets
Year Assets Growth
2002 60.663.000
2003 48.879.000 -24.11%
2004 64.949.000 24.74%
2005 141.274.000 54.03%
2006 275.777.000 48.77%
2007 221.490.000 -24.51%
2008 245.085.000 9.63%
2009 194.235.000 -26.18%
2010 196.308.228 1.06%
2011 200.163.708 1.93%
2012 212.589.983 5.85%
2013 224.320.553 5.23%
2014 228.204.672 1.7%
2015 217.572.180 -4.89%
2016 50.268.000 -332.82%
2017 61.775.340 18.63%
2018 119.243.000 48.19%
2019 136.660.000 12.74%
2020 504.949.000 72.94%
2021 1.300.818.000 61.18%
2022 1.370.898.000 5.11%
2023 1.334.784.000 -2.71%
2023 1.093.642.000 -22.05%
2024 1.090.843.000 -0.26%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Carasent ASA Liabilities
Year Liabilities Growth
2002 7.117.000
2003 6.738.000 -5.62%
2004 13.336.000 49.48%
2005 70.992.000 81.21%
2006 91.402.000 22.33%
2007 101.276.000 9.75%
2008 100.195.000 -1.08%
2009 72.804.000 -37.62%
2010 89.717.892 18.85%
2011 86.129.784 -4.17%
2012 97.744.382 11.88%
2013 93.529.233 -4.51%
2014 146.302.584 36.07%
2015 146.105.903 -0.13%
2016 1.218.880 -11886.9%
2017 509.114 -139.41%
2018 27.811.000 98.17%
2019 46.083.000 39.65%
2020 103.973.000 55.68%
2021 129.543.000 19.74%
2022 144.296.000 10.22%
2023 269.825.000 46.52%
2023 138.236.000 -95.19%
2024 155.826.000 11.29%

Carasent ASA Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
3.51
Net Income per Share
-0.14
Price to Earning Ratio
-125.35x
Price To Sales Ratio
5.13x
POCF Ratio
43.15
PFCF Ratio
-60.48
Price to Book Ratio
1.39
EV to Sales
3.83
EV Over EBITDA
39.49
EV to Operating CashFlow
32.21
EV to FreeCashFlow
-45.14
Earnings Yield
-0.01
FreeCashFlow Yield
-0.02
Market Cap
1,30 Bil.
Enterprise Value
0,97 Bil.
Graham Number
6.46
Graham NetNet
3.63

Income Statement Metrics

Net Income per Share
-0.14
Income Quality
-2.96
ROE
-0.01
Return On Assets
-0.01
Return On Capital Employed
-0.03
Net Income per EBT
0.72
EBT Per Ebit
0.45
Ebit per Revenue
-0.13
Effective Tax Rate
0.28

Margins

Sales, General, & Administrative to Revenue
0.19
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.25
Operating Profit Margin
-0.13
Pretax Profit Margin
-0.06
Net Profit Margin
-0.04

Dividends

Dividend Yield
0.1
Dividend Yield %
10.22
Payout Ratio
-12.81
Dividend Per Share
1.84

Operating Metrics

Operating Cashflow per Share
0.42
Free CashFlow per Share
-0.3
Capex to Operating CashFlow
1.71
Capex to Revenue
0.2
Capex to Depreciation
0.92
Return on Invested Capital
-0.02
Return on Tangible Assets
-0.02
Days Sales Outstanding
82.05
Days Payables Outstanding
32.7
Days of Inventory on Hand
0
Receivables Turnover
4.45
Payables Turnover
11.16
Inventory Turnover
0
Capex per Share
0.71

Balance Sheet

Cash per Share
5,19
Book Value per Share
12,93
Tangible Book Value per Share
7.36
Shareholders Equity per Share
12.93
Interest Debt per Share
0.16
Debt to Equity
0.01
Debt to Assets
0.01
Net Debt to EBITDA
-13.42
Current Ratio
3.94
Tangible Asset Value
0,53 Bil.
Net Current Asset Value
0,28 Bil.
Invested Capital
776947000
Working Capital
0,33 Bil.
Intangibles to Total Assets
0.37
Average Receivables
0,06 Bil.
Average Payables
0,02 Bil.
Average Inventory
0
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Carasent ASA Dividends
Year Dividends Growth
2015 1
2016 2 0%
2018 0 0%
2023 2 100%

Carasent ASA Profile

About Carasent ASA

Carasent ASA provides cloud-based medical record services to the health care industry in the Nordic region. The company develops Webdoc, a cloud based EMR-system; and VĂ„rdrummet, a digital platform for interactive health care that enables healthcare providers to communicate with their patients through digital services, such as video, chat, and other channels. It also provides Ad Voca, Ad Opus, and Ad Curis. The company was formerly known as Apptix ASA and changed its name to Carasent ASA in May 2019. Carasent ASA was founded in 1997 and is based in Oslo, Norway.

CEO
Mr. Daniel Ohman
Employee
165
Address
Oevre Slottsgate 2B
Oslo, 0157

Carasent ASA Executives & BODs

Carasent ASA Executives & BODs
# Name Age
1 Vilma Jonson
Head of Strategy
70
2 Stefan Jernberg
Chief Compliance Officer
70
3 Mr. Niclas Hugosson
Founder,Chief Product Officer & Business Developer
70
4 Anna Holmen Larsson
People and Culture Manager
70
5 Mr. Chris Damvakaris
Vice President of Sales & Business Development
70
6 Mr. Svein Martin Bjornstad
Chief Financial Officer
70
7 Mr. Daniel Ohman
Chief Executive Officer
70
8 Johan Eltes
Chief Technical Officer
70
9 Advocate Jon Schultz
Legal Counsel
70
10 Cornelia Broqvist
Chief Marketing Officer
70

Carasent ASA Competitors

Smart Eye AB (publ) Logo
Smart Eye AB (publ)

SEYE.ST

(1.5)
BerGenBio ASA Logo
BerGenBio ASA

BGBIO.OL

(1.8)
Kitron ASA Logo
Kitron ASA

KIT.OL

(1.8)
Nekkar ASA Logo
Nekkar ASA

NKR.OL

(1.8)